We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » More Generics Companies Are Targeting Teva’s Copaxone 40 mg Blockbuster
More Generics Companies Are Targeting Teva’s Copaxone 40 mg Blockbuster
Generics manufacturers Mylan, Momenta and Sandoz have joined Dr. Reddy’s Laboratories as some of the first to announce patent challenges against Teva’s blockbuster multiple sclerosis drug Copaxone in the newer 40 mg version.